Global Meningococcal Vaccine Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
- Request Covid Impact
- Table of Content
- List of Companies
- Inquiry Before Buying
- Request for Customization
“Global Meningococcal Vaccine Market” is the title of an upcoming report offered by MarketResearch.Biz. The report contains information and data, and inputs from both primary and secondary data sources, that have been verified and validated by experts in the target market. The report presents a thorough study of revenues, historical data, and information, key developments, and strategies by major players that offer vital insights and perspectives in to various scenarios market. Besides critical data and related information, the report includes key trends (both present and future), factors that are driving market growth, factors that are or could be potential restraints to market growth, as well as opportunities that can be leveraged for potential revenue generation in untapped regions and countries. It also covers threats or challenges for existing as well as new entrants in the market. The global meningococcal vaccine market has been segmented on the basis of type, brand, age group, as well as regions and countries.
Meningococcal vaccine, refers to any of the vaccines used to prevent infection by Neisseria meningitidis. Different versions are effective against some or all of the following types of meningococcus: A, B, C, W-135, and Y. The vaccines are between 85-100% effective for at least 2 years.
The increasing prevalence of meningitis across the world is a primary factor that is expected to continue to boost the revenue growth of the global meningococcal vaccine market in the years to come. Moreover, the growing number of initiatives being undertaken by government and other authoritative organizations to combat the increasing incidence of this disease is also a factor that is slated to influence the market growth of this global industry over the next 10 years.
Additionally, the increasing presence of non-profit organization contributing to research projects, improved training programs being offered to healthcare professionals, as well as the supplementation of added support and information to individuals undergoing these treatments is a factor that is anticipated to have a positive influence on the revenue growth of the global meningococcal vaccine market in the coming years.
In light of the recent COVID-19 outbreak, the operations of numerous industries have been either temporarily halted or are functioning with a minimal workforce due to enforced lockdowns and imposed restrictions by respective governing bodies. The global meningococcal vaccine industry is no different, and this factor is expected to negatively impact market growth in the years to come.
Nonetheless, the fact that there are vaccines in the phase-3 stage of clinical trials and is expected to be made commercially available due the course of the forecast period is a factor that is expected to have a significant influence on the revenue growth of the global meningococcal vaccine market in the foreseeable future.
Segmentation of the global meningococcal vaccine market is as follows:
In terms of type, the quadrivalent meningococcal vaccines segment accounted for the maximum number of revenue shares of the global meningococcal vaccine market in 2020, and is indicative of indexing a high CAGR in the years to come. This can be attributed to the wide usage of existing products, as well as the increase in approval rates of new vaccines in this market. The other segment is also slated to register considerable revenue growth in the coming years.
With respect to brand, Bexsero accounted for the maximum number of revenue shares in 2020, and is slated to index considerable revenue growth over the next 10 years. This can be attributed to the factors such as lower costs, reduced dosages, as well as resulting fewer doctor visits, on account of its regular usage.
On the basis of age group, the infant segment accounted for the maximum number of revenue shares of the global meningococcal vaccine market, and is expected to index the fastest rate of revenue growth in the coming years.
Regional Segmentation and Analysis:
North America accounted for the highest number of revenue shares of the global meningococcal vaccine market in 2020, and is slated to continue doing so over the forecast period. The markets in Europe accounted for the second-highest number of revenue shares of this global market in 2020. This can be accredited to increasing investments being made towards R&D activities in this sector, as well as favorable initiatives.
The markets in the Asia Pacific region are also slated to index considerable revenue growth in the years to come, owing to increasing initiatives by government organizations to combat the spread of this disease, as well as the large pediatric patient pool in this region.
Segmentation of the Global Meningococcal Vaccine Market:
Segmentation by Type:
Segmentation by Brand:
Segmentation by Age Group:
Segmentation by Regions:
- North America
- South America
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2020 Estimated Year 2021 Forecast Period 2021–2030 Revenue in US$
- Pfizer Inc.
- Novartis International AG
- Sanofi S.A.
- Serum Institute of India Ltd.
- GlaxoSmithKline plc.
- Merck & Co. Inc.
Request for TOC
Don't just take our word. We are trusted by these great companies!